Loading…
CSPC Pharmaceutical Group unit making pharmaceutical raw ingredients like caffeine and health-food/vitamin products in China.
CSPC Pharmaceutical Group unit making pharmaceutical raw ingredients like caffeine and health-food/vitamin products in China.
Bulk ingredients such as caffeine are sold in volume to drink and pharmaceutical makers at prices that follow supply and demand, while the branded health-food and vitamin lines are sold to consumers through retail channels.
Moat: narrow (scale, process know-how). Major global supplier of caffeine and related bulk pharmaceutical ingredients.
Headquarters: Shijiazhuang, China · Founded: 2006 · Employees: 2,369
Size CSPC Innovation Pharmaceutical (300765.SZ) is a China Consumer Staples company (Food: Major Diversified) with a market value of $6.48B, the 381st largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥34.65 on 6 Nov 2026.
Performance Over six months the shares gained 14.1%, against +2.6% for the median peer and -16.4% for the China market (cap-weighted) — 3rd highest of 14 in its peer set.
Growth Revenue grew 116.8% over the last twelve months (peer median +2.0%); the operating margin is 26.1% (peer median 11.2%).
Valuation It trades at 40.6× forward earnings against a peer median of 15.4× (most expensive of 13).
Price implies For today's price to make sense, revenue must grow about 14% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is +3 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 25.8 points above its cost of capital (7.0% WACC).
Next results Next results expected around 12 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥4.54B | CN¥2.15B | CN¥1.97B | CN¥2.52B | CN¥2.61B |
| Revenue growth | — | +9% | -22% | -4% | — |
| Gross profit | CN¥3.10B | CN¥688M | CN¥688M | CN¥1.07B | CN¥1.11B |
| EBITDA | n/a | -CN¥403M | -CN¥59.5M | CN¥308M | CN¥819M |
| Net income | CN¥993M | -CN¥241M | CN¥53.7M | CN¥434M | CN¥726M |
| Free cash flow | CN¥2.05B | -CN¥764M | -CN¥1.71B | CN¥140M | CN¥530M |
| Capital expenditure | CN¥613M | CN¥568M | CN¥478M | CN¥581M | CN¥114M |
| Total debt | CN¥890M | CN¥107M | CN¥93.7M | CN¥1.65M | CN¥40.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| CSPC Innovation Pharmaceutical 300765.SZ | $6.48B | +14% | +117% | 26% | 40.6× | 13.9% |
| Cspc Pharma 1093.HK | $12.4B | +5% | +25% | 28% | 9.3× | -10.3% |
| COFCO Biotechnology 000930.SZ | $1.32B | -21% | -9% | -2% | n/a | n/a |
| Northeast Pharmaceutical 000597.SZ | $948M | -10% | -6% | 3% | n/a | -6.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300765.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -23.2% | +7.7% | 2nd lowest of 14 |
| 6-month return | +14.1% | +2.6% | 3rd highest of 14 |
| Distance from 52-week high | -33.1% | -22.8% | 4th lowest of 14 |
| Revenue growth (TTM) | +116.8% | +2.0% | highest of 14 |
| Operating margin | 26.1% | 11.2% | 2nd highest of 14 |
| Forward P/E | 40.6× | 15.4× | most expensive of 13 |
| Growth the price implies (Req g, 7 yrs) | 13.9% | 0.6% | 2nd most demanding of 12 |
| Growth delivered (Del g) | +10.5% | +3.6% | 4th highest of 12 |
| Hurdle (Req g minus delivered) | +3.4 pp | +0.1 pp | 3rd most demanding of 12 |
| ROIC minus cost of capital | +25.8 pp | +3.4 pp | 2nd highest of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| CSPC Innovation Pharmaceutical 300765.SZ | China | $6.48B | +14% | +117% | 26% | 40.6× | 13.9% | +10.5% |
| SamyangFood 003230.KS | South Korea | $6.70B | -9% | +38% | 23% | 16.3× | -6.6% | +29.4% |
| Hebei Yangyuan Zhihui Beverage 603156.SS | China | $6.06B | -15% | +12% | 28% | 26.5× | 9.9% | +3.9% |
| Conagra Brands CAG | United States | $7.28B | +8% | -2% | 11% | 10.6× | -4.9% | +0.2% |
| Kewpie 2809.T | Japan | $4.07B | +11% | +4% | 7% | 24.2× | 0.6% | -0.7% |
| Olam VC2.SI | Singapore | $2.55B | -29% | -40% | 2% | 17.6× | -3.7% | -3.7% |
| Chagee Holdings Limited Unsponsored ADR CHA | United States | $2.44B | +19% | 0% | 11% | 7.9× | -4.1% | +190.8% |
| Associated British Foods ABF.L | United Kingdom | $18.7B | +11% | +1% | 7% | 13.5× | 7.8% | +7.1% |
| General Mills GIS | United States | $19.0B | +2% | -4% | 15% | 11.4× | -6.7% | +0.3% |
| ITO EN,Ltd 2593.T | Japan | $2.12B | +14% | +5% | 5% | 26.0× | n/a | n/a |
| Dongsuh 026960.KS | South Korea | $2.06B | +6% | +6% | 8% | n/a | 16.2% | +1.6% |
| Yihai International 1579.HK | Hong Kong | $2.02B | +3% | +11% | 18% | 14.2× | 6.8% | +3.6% |
| Yihai Kerry Arawana 300999.SZ | China | $21.3B | -8% | +2% | 1% | 37.3× | n/a | n/a |
| Yankershop Food 002847.SZ | China | $1.64B | -30% | 0% | 14% | 14.6× | 2.9% | +24.1% |